Vulvar Melanomda c-KIT Gen Varyantı Moleküler Tedavi için Bir Şans Olabilir mi? A Variant of the c-KIT gene in Vulvar Melanoma May Be a Chance of Molecular Therapy?
Öz
Anahtar Kelimeler
Destekleyen Kurum
Proje Numarası
Teşekkür
Kaynakça
- Referans1 Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021;71(1):7-33.
- Referans2 Gadducci A, Carinelli S, Guerrieri ME, Aletti GD. Melanoma of the lower genital tract: Prognostic factors and treatment modalities. Gynecol Oncol. 2018;150(1):180-9.
- Referans3 Carvajal RD, Antonescu CR, Wolchok JD, Chapman PB, Roman RA, Teitcher J, et al. KIT as a therapeutic target in metastatic melanoma. Jama. 2011;305(22):2327-34.
- Referans4 Gradishar WJ, Anderson BO, Abraham J, Aft R, Agnese D, Allison KH, et al. Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN. 2020;18(4):452-78.
- Referans5 Sugiyama VE, Chan JK, Shin JY, Berek JS, Osann K, Kapp DS. Vulvar melanoma: a multivariable analysis of 644 patients. Obstetrics & Gynecology. 2007;110(2 Part 1):296-301.
- Referans6 AACR Project GENIE: Powering Precision Medicine through an International Consortium. Cancer discovery. 2017;7(8):818-31.
- Referans7 Wohlmuth C, Wohlmuth-Wieser I. Vulvar Melanoma: Molecular Characteristics, Diagnosis, Surgical Management, and Medical Treatment. Am J Clin Dermatol. 2021 Sep;22(5):639-651.
- Referans8 Mangana J, Levesque MP, Karpova MB, Dummer R. Sorafenib in melanoma. Expert opinion on investigational drugs. 2012;21(4):557-68.
Ayrıntılar
Birincil Dil
İngilizce
Konular
Cerrahi
Bölüm
Olgu Sunumu
Yazarlar
Makbule Nihan Somuncu
*
Türkiye
Sıtkı Özbilgeç
0000-0002-4776-4791
Türkiye
Emine Türen Demir
0000-0001-5510-4411
Türkiye
Ali Acar
0000-0002-9074-258X
Türkiye
Yayımlanma Tarihi
5 Haziran 2022
Gönderilme Tarihi
28 Mart 2022
Kabul Tarihi
29 Mayıs 2022
Yayımlandığı Sayı
Yıl 2022 Cilt: 22 Sayı: 2